Introduction
Chlamydia trachomatis is a common worldwide cause of sexually transmitted diseases (STDs), with about 50 million cases each year.' Since many of these infections are asymptomatic, they are not treated and can lead to severe complications, especially in women.2 The detection of this organism in the clinical laboratory is essential for the effective treatment and control of spread of infection.
Despite a sensitivity of less than 100%, cell culture is still considered to be the reference method for chlamydia detection.3 This technique is time-consuming, labour-intensive and requires trained personnel and optimal conditions of transport and storage of clinical specimens to ensure the chlamydia are alive and infectious. Alternative The AmplicorTM C trachomatis PCR test was performed on the 218 endocervical swabs, the 56 male urine samples and six male urethral swabs. Endocervical swabs in Amplicor specimen transport medium were stored at 4°C. FVU were centrifuged at 2,500 g for 10 minutes at room temperature, the supernatants were discarded and the pellets stored at -70°C until the AmplicorTM was performed as previously described. 12 Urine pellets were processed following the manufacturer's instructions. Specimens were considered positive when the optical density (OD) values at 450 nm were greater than 0.5, and negative when the OD values were less than 0.25. Specimens with OD values between 0.25 and 0.5 (grey zone) were tested again.
ANALYSIS OF DISCREPANT RESULTS
Discrepant results were analysed by doing the different tests a second time from the remaining clinical specimens stored at -70'C. The specimens were retested by LCR without modification of the initial protocol and by AmplicorTM after ten-fold dilution in AmplicorTM specimen transport medium for swabs or in urine dilution buffer for FVU. Samples with discordant AmplicorTm and LCR results and a negative culture, were submitted to PCR by using primers CT1/CT2 directed against the ompl gene (outer membrane protein) on the 2SP culture transport medium.5
STATISTICAL ANALYSIS
A clinical specimen was considered to be truly positive if either the cell culture was positive or both LCR and AmplicorTM results were positive or ompl-PCR positive when LCR and AmplicorTm gave discordant results. A clinical specimen was considered to be truly negative when the cell culture and at least one of the two other test results were both negative.
Results
A total of 280 patients were tested by using the three detection methods, LCR, Amplicor.m and cell culture. There was a good correlation among the three techniques, even without arbitration of discrepant results, since 269 of the 280 patients (96%) had totally concordant results (table 1) . Of these 269 patients, 14 were positive (six men and eight women) and 255 were negative by all the techniques used. Of the 14 patients with concordant positive results, six men had LCR-positive results on both urethral and urine specimens, positiveAmplicorTm on urine and positive-culture results on urethral swabs. Eight women detected as positive for C trachomatis infection had positive LCR, AmplicorTm and culture on endocervical swabs, and four of them had pos- 
Discussion
New diagnostic assays using molecular techniques have been developed, especially to diagnose and control STDs. Because of the better sensitivity of these tests, DNA amplification has been used on organisms that are difficult or impossible to culture.' PCR and LCR techniques have been applied on C trachomatis and are now (AmplicorTM) or will soon (L) be commercially available. The new LC2R test has been evaluated in our laboratory, on genital and urine specimens from both men and women. The LCR results have been compared with those obtained using AmplicorTM and cell culture. The overall LCR sensitivity was 95.2%, and its specificity was 99-6%. Previous data on LCR performed on urogenital specimens'3-15 reported sensitivities from 81 to 100%, and specificities from 93.5 to 100% depending on the specimens. The sensitivity and specificity values and the differences between the tests observed in our study, cannot be generalised because there were too few positive specimens. Differences in sensitivity are usually even more pronounced in low-risk than in high-risk population and the overall sensitivity is lower in specimens from males than from females. 17 Only a small number of techniques have been demonstrated to be suitable for the detection of C trachomatis in urine. Urine culture as well as enzyme immunoassays performed on female FVVU is very insensitive. '4 18 AmplicorTM has proved to be convenient for the detection of C trachomatis in males.'920 In our study, LCR results on male urine samples were almost identical to those obtained with urethral swabs by the same technique (except case 6). With AmplicorTM, a duplicate test was necessary for cases 1 and 2. After resolution of discrepancies, the results obtained on male urethral and urine samples were in complete agreement. In another study,2' LCR assay of male FVU was much more sensitive than culture of a urethral swab. Of the 97 cases where LCR was performed on female urines and endocervical swabs, the results were in agreement except for two cases (cases 9,10). These cases may be explained by there being only urethral or cervical C trachomatis localisations. Infections localised only in the urethra have been reported in a range of 5 to 30% of infected women and cervical infections alone in about 30%.'5 It would be possible to resolve the cases with positive LCR results only from urines by a confirmatory LCR, using probes targeting another sequence on the plasmid or directed to the major outer membrane protein gene, as described by Schachter et al.14 In a recent study,22 LCR assay performed on urine samples showed a detection rate almost 30% greater than that of endocervical swab culture.
In conclusion, both LCR and PCR tests appear to be promising for the diagnosis of C trachomatis infections in the urogenital tract from men and women. The LCR is a simple, rapid and easy to perform test. However, both LCR and AmplicorTM tests will become truly reliable when they are entirely automated, avoiding any potential contamination of the clinical samples. Similarly, to avoid false-negative results due to inhibitors present in the samples, an internal control monitoring the effectiveness of the reaction (LCR or PCR) will be necessary.
